Ferring 
Welcome,         Profile    Billing    Logout  
 29 Products   56 Diseases   29 Products   158 Trials   7362 News 


«12345678910111213...9596»
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Journal:  Common molecular basis for MASH and hepatitis C revealed via systems biology approach. (Pubmed Central) -  Nov 28, 2024   
    We extracted 10 hub genes between MASH and hepatitis C, and performed a series of analyses on the genes. Molecular docking and in vitro studies have revealed that Budesonide can effectively suppress the progression of MASH and hepatitis C. This study can provide novel insights into the potential drug targets and biomarkers for MASH and hepatitis C.
  • ||||||||||  Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
    Enrollment change, Trial withdrawal:  ABLE-42: A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS  (clinicaltrials.gov) -  Nov 22, 2024   
    P4,  N=0, Withdrawn, 
    Molecular docking and in vitro studies have revealed that Budesonide can effectively suppress the progression of MASH and hepatitis C. This study can provide novel insights into the potential drug targets and biomarkers for MASH and hepatitis C. N=25 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Opdivo (nivolumab) / BMS, Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date:  Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery (clinicaltrials.gov) -  Nov 19, 2024   
    P2,  N=60, Recruiting, 
    The findings of this population PK analysis support the maintenance of established certolizumab pegol dosing regimens throughout pregnancy. Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Role of Mifepristone in Induction of Labor in Full-Term Pregnancy. (Pubmed Central) -  Nov 18, 2024   
    Birth outcomes were consistent in both groups with no neonatal mortality. Conclusion Oral mifepristone has proved as a promising agent as a uterine sensitizer in inducing labor as it has significantly decreased induction to delivery time.
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Review, Journal:  Pain Management During Intrauterine Device Insertion in Nulliparous Women: A Scoping Review. (Pubmed Central) -  Nov 18, 2024   
    Alternatively, 500 mg of naproxen sodium taken prior to IUD insertion showed a significant reduction in post-IUD insertion pain (p=0.01) but did not show any significant reduction in pain during cervical grasping or during IUD insertion into the uterus...Furthermore, cervical softening and dilation with dinoprostone 3 mg and misoprostol 3 mg demonstrated a reduction in pain during all stages of IUD insertion and after insertion (p<0.01)...Additionally, there has been some research examining the impact of verbal analgesics, which involves the provider using a calm, soothing voice and slow speech to put the patient at ease, and the role that anxiety about IUD insertion can influence pain, but further research is needed to determine its significance. This research provides valuable insight into enhancing the improvement of pain during and after the insertion of IUDs for nulliparous women.
  • ||||||||||  Adstiladrin (nadofaragene firadenovec-vncg) / Ferring, Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal:  Bacillus Calmette-Gu (Pubmed Central) -  Nov 18, 2024   
    The last years have been exciting regarding new developments in this field after a long period of stagnation. Unfortunately, data available on some alternative therapies are mainly limited mainly to Phase I or II studies with a lack of robust evidence, but a clear trend in future treatments has just been drawn.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Journal:  Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. (Pubmed Central) -  Nov 16, 2024   
    These observations underscore the critical role of timing and disease context in order to optimize the therapeutic efficacy of immune modulators combined with androgen ablation, for which the presurgical neoadjuvant setting may be ideal. Our findings warrant future prospective validation, which is currently underway.
  • ||||||||||  Journal:  Structure-Activity Relationships and Target Selectivity of Phenylsulfonylamino-Benzanilide Inhibitors Based on S1647 at the SLC10 Carriers ASBT, NTCP, and SOAT. (Pubmed Central) -  Nov 14, 2024   
    The peptide drug bulevirtide blocks binding of the hepatitis B and D viruses to NTCP and thereby inhibits the virus's entry into hepatocytes...The present study aimed to comparatively analyze a set of newly synthesized and commercially available S1647 derivatives for their transport inhibition against ASBT, NTCP, and SOAT. Structure-activity relationships were systematically analyzed regarding potency and target specificity to elucidate whether this compound class is worth being further developed in preclinical studies for pharmacological ASBT, NTCP, and/or SOAT inhibition.
  • ||||||||||  Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
    Enrollment change:  ABLE-41: ADSTILADRIN Early Utilization and Outcomes in the Real World Setting (clinicaltrials.gov) -  Nov 13, 2024   
    P=N/A,  N=400, Recruiting, 
    AoP may be a useful sonographic parameter for predicting successful vaginal delivery among nulliparous women at late term undergoing IoL; an AOP wider than 100 N=800 --> 400
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie
    Upadacitinib exposure during pregnancy in seronegative Rheumatoid arthritis () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_12;    
    In patients with preexisting cardiovascular disease at baseline, a lower rate of further CVEs and treatment-related deaths was observed with degarelix. She has no history of spontaneous abortions.At the time of her RA diagnosis, the patient was considering pregnancy and was initially started on sulfasalazine...Despite this treatment, she exhibited only a partial response with ongoing disease activity, leading to a change to etanercept in August 2021.When etanercept proved ineffective, adalimumab was considered in January 2022...She was subsequently started on certolizumab...Access to a medical obstetrician team is invaluable in managing such cases.
  • ||||||||||  Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
    Trial completion date, Trial primary completion date, Combination therapy:  INFINITE: Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma (clinicaltrials.gov) -  Nov 7, 2024   
    P3,  N=53, Active, not recruiting, 
    She has no history of spontaneous abortions.At the time of her RA diagnosis, the patient was considering pregnancy and was initially started on sulfasalazine...Despite this treatment, she exhibited only a partial response with ongoing disease activity, leading to a change to etanercept in August 2021.When etanercept proved ineffective, adalimumab was considered in January 2022...She was subsequently started on certolizumab...Access to a medical obstetrician team is invaluable in managing such cases. Trial completion date: Nov 2024 --> Apr 2026 | Trial primary completion date: Nov 2023 --> Mar 2024
  • ||||||||||  Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
    Journal, Metastases:  Severe neutropenia caused by palliative radiation therapy in a case of metastatic hormone-sensitive prostate cancer. (Pubmed Central) -  Nov 5, 2024   
    On day 35 after treatment, severe neutropenia necessitated treatment interruption and required 23?days for neutrophil recovery with a granulocyte colony-stimulating factor agent. Owing to the severe hematologic toxicity caused by extensive radiation therapy for multiple bone lesions, treatment prioritization by lesion and avoiding irradiation of the red bone marrow is essential.
  • ||||||||||  Siliq (brodalumab) / Bausch Health, Humira (adalimumab) / AbbVie
    Induction Cost Per Responder of Brodalumab Compared With Other Biologic Therapies for Patients With Moderate to Severe Plaque Psoriasis in Canada () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3175;    
    The CPR was estimated as the drug acquisition costs during the induction period multiplied by the number needed to treat (NNT) for achieving PASI 75, 90, or 100 for the following treatments: adalimumab (innovator and SEB), brodalumab, bimekizumab, certolizumab pegol, etanercept (innovator and SEB), guselkumab, infliximab (innovator and SEB), ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab (innovator and SEB). These results demonstrate that brodalumab has the lowest induction CPR across all PASI outcomes compared to other biologic therapies, including SEB therapies, thus providing the best value for money for patients, prescribers, and payers.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Cosentyx (secukinumab) / Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
    Cost of Biologics in Patients Suffering From Psoriasis in Greece: A Retrospective Longitudinal Cohort Study () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1158;    
    The study highlights significant variability in biologic treatment costs for PsO, influenced by drug, persistence, and prior treatment history. These findings underscore the importance of balancing clinical efficacy and economic impact in treatment decisions for PsO, ensuring effective care while managing healthcare resources efficiently.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Facial Hyperpigmentation Following Adalimumab. (Pubmed Central) -  Nov 1, 2024   
    inhibitors. Clinicians should consider this potential side effect in patients presenting with hyperpigmentation, and sun protection should be recommended as a preventive measure.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring, Aliqopa (copanlisib) / Bayer
    Enrollment change, Trial withdrawal:  A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer (clinicaltrials.gov) -  Oct 31, 2024   
    P1/2,  N=0, Withdrawn, 
    https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=368435, Identifier CRD42022368435. N=37 --> 0 | Active, not recruiting --> Withdrawn
  • ||||||||||  Zinplava (bezlotoxumab) / Merck (MSD), Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
    Review, Journal:  Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection. (Pubmed Central) -  Oct 26, 2024   
    Live biotherapeutic products provide a safe and effective option for the prevention of rCDI and represent an improvement over conventional FMT. Additional studies are needed to further determine their place in therapy relative to bezlotoxumab and in the setting of immunosuppression and inflammatory bowel disease.
  • ||||||||||  Hernicore (condoliase) / Seikagaku, Ferring
    Journal:  Efficacy of Chemonucleolysis with Condoliase in Patients Aged under 20 Years. (Pubmed Central) -  Oct 14, 2024   
    Caution should be taken when managing cases showing lumbar instability or existing disability. While chemonucleolysis with condoliase is a less invasive treatment option for LDH, the administration should be decided upon with sufficient consent considering the potential limited efficacy and disk degeneration.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring, Aliqopa (copanlisib) / Bayer
    Enrollment closed:  A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer (clinicaltrials.gov) -  Oct 8, 2024   
    P1/2,  N=37, Active, not recruiting, 
    While chemonucleolysis with condoliase is a less invasive treatment option for LDH, the administration should be decided upon with sufficient consent considering the potential limited efficacy and disk degeneration. Recruiting --> Active, not recruiting
  • ||||||||||  Journal:  Novel intravesical therapies and delivery systems for the management of bladder cancer. (Pubmed Central) -  Oct 8, 2024   
    The armamentarium for the treatment of bladder cancer patients is expanding, notably with HIVEC, hydrogels, drug-RIS and novel therapies. However, accurate patients' selection is key to prevent disease progression in any bladder-sparing strategy, and radical cystectomy remains the gold-standard to date.
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Journal:  Factors Influencing Induction of Labor Success in Riyadh, Saudi Arabia. (Pubmed Central) -  Oct 4, 2024   
    However, lower gravidity (?3) and Propess medication could lead to operative procedures among pregnant women. Hence, it is necessary to carefully assess the condition of pregnant women before directing them to IOL.
  • ||||||||||  Hernicore (condoliase) / Seikagaku, Ferring
    Review, Journal:  Treatment Gaps and Emerging Therapies in Lumbar Disc Herniation. (Pubmed Central) -  Oct 3, 2024   
    Hence, it is necessary to carefully assess the condition of pregnant women before directing them to IOL. The lack of sustained benefits associated with ESIs and the risks associated with surgery underscore the unmet need for novel, minimally invasive interventional therapies able to address the underlying nerve root compression in LDH.